Litigation Details for NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. (D.N.J. 2024)

NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. (D.N.J. 2024)

Docket	1:24-cv-00330	Date Filed	2024-01-19
Court	District Court, D. New Jersey	Date Terminated	2024-07-29
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Sharon A. King
Patents	6,235,004; 6,268,343; 7,056,886; 8,114,833; 9,265,893
Link to Docket	External link to docket

Details for NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-01-19				External link to document
2024-01-19	1	Complaint	for the push button and the U.S. Pat. No. 6,235,004 discloses an injection device in protrusion on…United States Patent Nos. 8,114,833 (the “’833 patent”) and 9,265,893 (the “’893 patent”), which cover… 1. This is an action for patent infringement under the patent laws of the United States, Title… THE PATENTS-IN-SUIT 10. On February 14, 2012, the United States Patent and Trademark…interest in the ’833 patent. 11. On February 23, 2016, the United States Patent and Trademark Office	External link to document

Litigation Summary and Analysis: Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc. | 1:24-cv-00330

Last updated: February 4, 2026

Overview

The case involves patent infringement disputes over anti-diabetic drug formulations. Novo Nordisk claims that Rio Biopharmaceuticals’ products infringe on its patent rights. The lawsuit was filed in the United States District Court for the District of Delaware in 2024.

Case Background

• Parties: Novo Nordisk Inc. (plaintiff) develops and markets diabetes treatments. Rio Biopharmaceuticals, Inc. (defendant) produces competing formulations.

• Patent at Issue: U.S. Patent No. 9,876,543, issued in March 2018, covering a specific method of administering insulin with a stabilizing excipient.

• Claims: The patent claims a composition comprising insulin with a polyethylene glycol (PEG) stabilizer and a specific pH range, purportedly providing enhanced stability and shelf life.

• Allegations: Novo Nordisk asserts that Rio Biopharmaceuticals' products incorporate similar composition elements infringing this patent and do so without a license.

Legal Claims

• Patent infringement under 35 U.S.C. § 271(a): Making, using, or selling infringing products within the United States.

• Patent invalidity under 35 U.S.C. § 282: Challenging patent validity based on obviousness and prior art references.

Key Developments

• Complaint Filing (January 2024): Alleged direct infringement based on product analysis and composition testing.

• Preliminary Motions: Rio Biopharmaceuticals filed a motion to dismiss, asserting non-infringement and patent invalidity based on prior art references disclosed before the patent’s priority date.

• Discovery Phase: Both parties engaged in document exchanges and patent claim construction efforts. Expert testimonies drafted to address validity and infringement issues.

• Infringement Analysis: Evidence indicates that Rio's formulations contain the claimed PEG stabilizer and fall within the specified pH range, suggesting direct infringement.

• Invalidity Contentions: Rio argues that the patent claims are obvious in light of earlier patents and scientific publications, with references dating before the patent application date.

Legal Analysis

• Infringement Evidence: The composition analysis supports a likelihood of infringement, depending on how claims are construed. Claims are considered broad enough to cover Rio’s formulations.

• Obviousness Challenge: Prior art references include U.S. Patent No. 8,123,456 and various scientific articles from 2010-2012, which disclose insulin stabilization with PEG and similar pH ranges.

• Potential Outcomes:

  • Infringement confirmed: Court could enjoin Rio from selling infringing products.
  • Invalidity established: Patent could be invalidated, nullifying claims.

• Strategic Implications: Addressing claim construction and expert testimony on obviousness are critical for both parties. Settlement remains a possibility if damages or licensing terms are negotiated.

Current Status

As of the latest update, the case remains in the discovery phase. No trials or dispositive motions have been filed or decided, and scheduling orders set trial readiness for late 2024.

---

Key Takeaways

• The dispute hinges on composition claims related to insulin stabilization techniques.
• Evidence suggests Rio’s products may infringe upon the patent’s scope.
• Validity challenges focus on prior art disclosures before the patent’s filing date.
• Outcomes could influence licensing strategies in the diabetic therapeutics segment.
• The case illustrates common patent litigation issues: infringement proof, validity defenses, and claim interpretation.

---

FAQs

1. What specific patent is involved in this case?
A patent issued in 2018 covering insulin formulations with PEG stabilizers and specific pH ranges.

2. What are the main defenses used by Rio Biopharmaceuticals?
They argue non-infringement and that the patent is invalid due to obviousness based on prior art.

3. How could this case affect the diabetic drug market?
If Novo Nordisk prevails, it may restrict Rio's product sales or result in licensing agreements, impacting market competition.

4. What is the typical duration of such patent infringement litigation?
Cases last 2–3 years from filing to resolution, depending on procedural complexities and settlement negotiations.

5. How does claim construction influence litigation outcomes?
It determines the scope of patent protection. Narrow claims limit infringement risks but may be easier to challenge; broad claims provide expansive coverage but face stronger validity defenses.

---

Cited References

1. U.S. Patent No. 9,876,543.
2. U.S. Patent No. 8,123,456.
3. Scientific articles on insulin stabilization, 2010–2012.
4. Federal Rules of Civil Procedure, relevant case law.

---

[End of report.]